RGEN - REPLIGEN CORP

132.7
0.710   0.535%

Share volume: 1,105,753
Last Updated: 04-21-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$131.99
0.71
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 28%
Dept financing 39%
Liquidity 75%
Performance 45%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
1.14%
1 Month
14.05%
3 Months
-20.98%
6 Months
-15.70%
1 Year
-4.48%
2 Year
-15.74%
Key data
Stock price
$132.70
P/E Ratio 
188.65
DAY RANGE
$131.30 - $141.46
EPS 
$0.87
52 WEEK RANGE
$109.66 - $175.77
52 WEEK CHANGE
-$6.15
MARKET CAP 
9.224 B
YIELD 
N/A
SHARES OUTSTANDING 
56.331 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-29-2025
BETA 
0.22
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$920,316
AVERAGE 30 VOLUME 
$844,243
Company detail
CEO: Tony J. Hunt
Region: US
Website: repligen.com
Employees: 2,020
IPO year: 1990
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company sells its products to life sciences, biopharmaceutical companies; laboratory researchers; and contract manufacturing organizations.

Recent news